|
1
|
Nagao-Kitamoto H, Setoguchi T, Kitamoto S,
Nakamura S, Tsuru A, Nagata M, Nagano S, Ishidou Y, Yokouchi M,
Kitajima S, et al: Ribosomal protein S3 regulates GLI2-mediated
osteosarcoma invasion. Cancer Lett. 356:855–861. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sevelda F, Mayr L, Kubista B, Lötsch D,
van Schoonhoven S, Windhager R, Pirker C, Micksche M and Berger W:
EGFR is not a major driver for osteosarcoma cell growth in vitro
but contributes to starvation and chemotherapy resistance. J Exp
Clin Cancer Res. 34:1342015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lewis VO: What's new in musculoskeletal
oncology. J Bone Joint Surg Am. 91:1546–1556. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Judson I, Verweij J, Gelderblom H,
Hartmann JT, Schöffski P, Blay JY, Kerst JM, Sufliarsky J, Whelan J
and Hohenberger P: Doxorubicin alone versus intensified doxorubicin
plus ifosfamide for first-line treatment of advanced or metastatic
soft-tissue sarcoma: A randomised controlled phase 3 trial. Lancet
Oncol. 15:415–423. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Miller BJ, Gao Y and Duchman KR:
Socioeconomic measures influence survival in osteosarcoma: An
analysis of the national cancer data base. Cancer Epidemiol.
49:112–117. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhang Y, Kwok-Shing Ng P, Kucherlapati M,
Chen F, Liu Y, Tsang YH, de Velasco G, Jeong KJ, Akbani R,
Hadjipanayis A, et al: A pan-cancer proteogenomic atlas of
PI3K/AKT/mTOR pathway alterations. Cancer Cell. 31:820–832. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Dowling RJ, Topisirovic I, Fonseca BD and
Sonenberg N: Dissecting the role of mTOR: Lessons from mTOR
inhibitors. Biochim Biophy Acta. 1804:433–439. 2010. View Article : Google Scholar
|
|
8
|
Fan QW and Weiss WA: Inhibition of
PI3K-Akt-mTOR signaling in glioblastoma by mTORC1/2 inhibitors.
Methods Mol Biol. 821:349–359. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hossen MJ, Hong YD, Baek KS, Yoo S, Hong
YH, Kim JH, Lee JO, Kim D, Park J and Cho JY: In vitro
antioxidative and anti-inflammatory effects of the compound k-rich
fraction BIOGF1K, prepared from panax ginseng. J Ginseng Res.
41:43–51. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chen L, Meng Y, Sun Q, Zhang Z, Guo X,
Sheng X, Tai G, Cheng H and Zhou Y: Ginsenoside compound K
sensitizes human colon cancer cells to TRAIL-induced apoptosis via
autophagy-dependent and -independent DR5 upregulation. Cell Death
Dis. 7:e23342016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Li W, Zhang M, Gu J, Meng ZJ, Zhao LC,
Zheng YN, Chen L and Yang GL: Hypoglycemic effect of
protopanaxadiol-type ginsenosides and compound k on type 2 diabetes
mice induced by high-fat diet combining with streptozotocin via
suppression of hepatic gluconeogenesis. Fitoterapia. 83:192–198.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wei S, Li W, Yu Y, Yao F, A L, Lan X, Guan
F, Zhang M and Chen L: Ginsenoside compound K suppresses the
hepatic gluconeogenesis via activating adenosine-5′monophosphate
kinase: A study in vitro and in vivo. Life Sci. 139:8–15. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ahuja A, Kim JH, Kim JH, Yi YS and Cho JY:
Functional role of ginseng-derived compounds in cancer. J Ginseng
Res. 42:248–254. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Muthukumar T, Aravinthan A, Sharmila J,
Kim NS and Kim JH: Collagen/chitosan porous bone tissue engineering
composite scaffold incorporated with ginseng compound K. Carbohydr
Polym. 152:566–574. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yang L, Zhang Z, Hou J, Jin X, Ke Z, Liu
D, Du M, Jia X and Lv H: Targeted delivery of ginsenoside compound
K using TPGS/PEG-PCL mixed micelles for effective treatment of lung
cancer. Int J Nanomedicine. 12:7653–7667. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yang XD, Yang YY, Ouyang DS and Yang GP: A
review of biotransformation and pharmacology of ginsenoside
compound K. Fitoterapia. 100:208–220. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Li Y, Zhou T, Ma C, Song W, Zhang J and Yu
Z: Ginsenoside metabolite compound K enhances the efficacy of
cisplatin in lung cancer cells. J Thorac Dis. 7:400–406.
2015.PubMed/NCBI
|
|
18
|
Yang L, Xin J, Zhang Z, Yan H, Wang J, Sun
E, Hou J, Jia X and Lv H: TPGS-modified liposomes for the delivery
of ginsenoside compound K against non-small cell lung cancer:
Formulation design and its evaluation in vitro and in vivo. J Pharm
Pharmacol. 68:1109–1118. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhang K and Li Y: Effects of ginsenoside
compound k combined with cisplatin on the proliferation, apoptosis
and epithelial mesenchymal transition in MCF-7 cells of human
breast cancer. Pharm Biol. 54:561–568. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lee S, Kwon MC, Jang JP, Sohng JK and Jung
HJ: The ginsenoside metabolite compound K inhibits growth,
migration and stemness of glioblastoma cells. Int J Oncol.
51:414–424. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kang KA, Piao MJ, Kim KC, Zheng J, Yao CW,
Cha JW, Kim HS, Kim DH, Bae SC and Hyun JW: Compound k, a
metabolite of ginseng saponin, inhibits colorectal cancer cell
growth and induces apoptosis through inhibition of histone
deacetylase activity. Int J Oncol. 43:1907–1914. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ren T, Zheng B, Huang Y, Wang S, Bao X,
Liu K and Guo W: Osteosarcoma cell intrinsic PD-L2 signals promote
inv asion and metastasis via the RhoA-ROCK-LIMK2 and autophagy
pathways. Cell Death Dis. 10:2612019. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yu X, Hu L, Li S, Shen J, Wang D, Xu R and
Yang H: Long non-coding RNA taurine upregulated gene 1 promotes
osteosarcoma cell metastasis by mediating HIF-1α via miR-143-5p.
Cell Death Dis. 10:2802019. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chawla SP, Staddon AP, Baker LH, Schuetze
SM, Tolcher AW, D'Amato GZ, Blay JY, Mita MM, Sankhala KK, Berk L,
et al: Phase II study of the mammalian target of rapamycin
inhibitor ridaforolimus in patients with advanced bone and soft
tissue sarcomas. J Clin Oncol. 30:78–84. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Moriceau G, Ory B, Mitrofan L, Riganti C,
Blanchard F, Brion R, Charrier C, Battaglia S, Pilet P, Denis MG,
et al: Zoledronic acid potentiates mTOR inhibition and abolishes
the resistance of osteosarcoma cells to RAD001 (Everolimus):
Pivotal role of the prenylation process. Cancer Res.
70:10329–10339. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Manara MC, Nicoletti G, Zambelli D,
Ventura S, Guerzoni C, Landuzzi L, Lollini PL, Maira SM,
García-Echeverría C, Mercuri M, et al: NVP-BEZ235 as a new
therapeutic option for sarcomas. Clin Cancer Res. 16:530–540. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Engelman JA, Luo J and Cantley LC: The
evolution of phosphatidylinositol 3-kinases as regulators of growth
and metabolism. Nat Rev Genet. 7:606–619. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Fruman DA and Rommel C: PI3K and cancer:
Lessons, challenges and opportunities. Nat Rev Drug Discov.
13:140–156. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
29
|
Gewinner C, Wang ZC, Richardson A,
Teruya-Feldstein J, Etemadmoghadam D, Bowtell D, Barretina J, Lin
WM, Rameh L, Salmena L, et al: Evidence that inositol polyphosphate
4-phosphatase type II is a tumor suppressor that inhibits PI3K
signaling. Cancer Cell. 16:115–125. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Hay N: Interplay between FOXO, TOR, and
AKT. Biochim Biophys Acta. 1813:1965–1970. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Laplante M and Sabatini DM: MTOR signaling
in growth control and disease. Cell. 149:274–293. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Mabuchi S, Hisamatsu T and Kimura T:
Targeting mTOR signaling pathway in ovarian cancer. Curr Med Chem.
18:2960–2968. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wu SH, Bi JF, Cloughesy T, Cavenee WK and
Mischel PS: Emerging function of mTORC2 as a core regulator in
glioblastoma: Metabolic reprogramming and drug resistance. Cancer
Biol Med. 11:255–263. 2014.PubMed/NCBI
|
|
34
|
Yuan H and Gao Y: MicroRNA-1908 is
upregulated in human osteosarcoma and regulates cell proliferation
and migration by repressing PTEN expression. Oncol Rep.
34:2706–2714. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kawano M, Tanaka K, Itonaga I, Ikeda S,
Iwasaki T and Tsumura H: MicroRNA-93 promotes cell proliferation
via targeting of PTEN in Osteosarcoma cells. J Exp Clin Cancer Res.
34:762015. View Article : Google Scholar : PubMed/NCBI
|
